Literature DB >> 10479666

Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL.

M S Gowri1, D R Van der Westhuyzen, S R Bridges, J W Anderson.   

Abstract

High plasma triglyceride concentrations in diabetic subjects increase their risk for developing coronary heart disease. Numerous studies have shown that the high density lipoprotein (HDL) composition is abnormal in type 2 diabetic subjects. One study has shown that HDL (lipoprotein A-I) isolated from subjects with non-insulin-dependent diabetes mellitus exhibits a decreased capacity to induce cholesterol efflux. The current study examined the effect of HDL(2) and HDL(3) subfractions from poorly controlled type 2 diabetic and control subjects on THP-1 macrophage-mediated low density lipoprotein (LDL) oxidation. The composition and protective effects of HDL(2), but not of HDL(3), differed significantly between control and diabetic subjects. HDL(2) from diabetics were triglyceride enriched and cholesterol depleted compared with those from controls. Control HDL(2) inhibited LDL oxidation, as assessed by lipid peroxides and electrophoretic mobility, significantly (P<0.05) more than did diabetic HDL(2) in both the fasting and postprandial state. In addition, HDL(2) from diabetics did not protect against apolipoprotein B-100 fragmentation in LDL. Cross-linking in apolipoprotein A-I, oxidized in the presence of LDL, was extensive in HDL(2) from diabetics compared with that from controls. Serum triglyceride concentrations were negatively correlated with protection by HDL(2) (r=-0.673, P<0.05) in diabetic but not in control subjects. HDL(2)-associated platelet-activating factor acetylhydrolase activity was positively correlated with protection by HDL(2) in control (r=0.872, P<0.002) but not in diabetic subjects. In conclusion, compositional alterations in HDL(2) from poorly controlled type 2 diabetic subjects may reduce its antiatherogenic properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479666     DOI: 10.1161/01.atv.19.9.2226

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  35 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Dysfunctional high-density lipoprotein and atherosclerosis.

Authors:  Shawn Ragbir; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

Review 3.  Anti-inflammatory properties of HDL.

Authors:  Benjamin J Ansell; Mohamad Navab; Karol E Watson; Gregg C Fonarow; Alan M Fogelman
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

4.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

5.  Oxidative mechanisms and atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Drug Discov Today Ther Strateg       Date:  2008-03

Review 6.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

7.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 8.  Alterations in lipoprotein defense against oxidative stress in metabolic syndrome.

Authors:  Boris Hansel; Anatol Kontush; Dominique Bonnefont-Rousselot; Eric Bruckert; M John Chapman
Journal:  Curr Atheroscler Rep       Date:  2006-11       Impact factor: 5.113

9.  PPAR-γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago.

Authors:  Steve Ian Smith
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  The ratio of high-density lipoprotein cholesterol to apolipoprotein A-I predicts myocardial injury following elective percutaneous coronary intervention.

Authors:  Xiao-Lin Li; Jian-Jun Li; Yuan-Lin Guo; Cheng-Gang Zhu; Ping Qing; Na-Qiong Wu; Bo Xu; Run-Lin Gao
Journal:  Clin Cardiol       Date:  2014-08-11       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.